Is an insertion/deletion polymorphism at miRNA-122 binding site in the IL1A associated with a reduced risk of cervical squamous cell carcinoma?
These findings indicate that the IL1A rs3783553 polymorphism may be associated with the etiology of CSCC.
This study shows that intravesical gemcitabine does not merit further study in this patient population. A tumor size of>1 cm may be a critical factor in accounting for the low response rate.